139 related articles for article (PubMed ID: 9755718)
1. Enzymology of tirapazamine metabolism: a review.
Patterson AV; Saunders MP; Chinje EC; Patterson LH; Stratford IJ
Anticancer Drug Des; 1998 Sep; 13(6):541-73. PubMed ID: 9755718
[TBL] [Abstract][Full Text] [Related]
2. Metabolism of tirapazamine by multiple reductases in the nucleus.
Delahoussaye YM; Evans JW; Brown JM
Biochem Pharmacol; 2001 Nov; 62(9):1201-9. PubMed ID: 11705453
[TBL] [Abstract][Full Text] [Related]
3. The role of cytochrome P450 and cytochrome P450 reductase in the reductive bioactivation of the novel benzotriazine di-N-oxide hypoxic cytotoxin 3-amino-1,2,4-benzotriazine-1,4-dioxide (SR 4233, WIN 59075) by mouse liver.
Walton MI; Wolf CR; Workman P
Biochem Pharmacol; 1992 Jul; 44(2):251-9. PubMed ID: 1642640
[TBL] [Abstract][Full Text] [Related]
4. Initial characterization of the major mouse cytochrome P450 enzymes involved in the reductive metabolism of the hypoxic cytotoxin 3-amino-1,2,4-benzotriazine-1,4-di-N-oxide (tirapazamine, SR 4233, WIN 59075).
Riley RJ; Hemingway SA; Graham MA; Workman P
Biochem Pharmacol; 1993 Mar; 45(5):1065-77. PubMed ID: 8461036
[TBL] [Abstract][Full Text] [Related]
5. Enzymology of the reductive bioactivation of SR 4233. A novel benzotriazine di-N-oxide hypoxic cell cytotoxin.
Walton MI; Workman P
Biochem Pharmacol; 1990 Jun; 39(11):1735-42. PubMed ID: 2344370
[TBL] [Abstract][Full Text] [Related]
6. Reduction of 3-amino-1,2,4-benzotriazine-1,4-di-N-oxide (tirapazamine, WIN 59075, SR 4233) to a DNA-damaging species: a direct role for NADPH:cytochrome P450 oxidoreductase.
Fitzsimmons SA; Lewis AD; Riley RJ; Workman P
Carcinogenesis; 1994 Aug; 15(8):1503-10. PubMed ID: 8055626
[TBL] [Abstract][Full Text] [Related]
7. Subcellular Location of Tirapazamine Reduction Dramatically Affects Aerobic but Not Anoxic Cytotoxicity.
Guise CP; Abbattista MR; Anderson RF; Li D; Taghipouran R; Tsai A; Lee SJ; Smaill JB; Denny WA; Hay MP; Wilson WR; Hicks KO; Patterson AV
Molecules; 2020 Oct; 25(21):. PubMed ID: 33105798
[TBL] [Abstract][Full Text] [Related]
8. Molecular enzymology of the reductive bioactivation of hypoxic cell cytotoxins.
Walton MI; Wolf CR; Workman P
Int J Radiat Oncol Biol Phys; 1989 Apr; 16(4):983-6. PubMed ID: 2703406
[TBL] [Abstract][Full Text] [Related]
9. Circadian changes of cytochrome P-450-dependent monooxygenase system in the rat liver.
Plewka A; Czekaj P; Kamiński M; Plewka D
Pol J Pharmacol Pharm; 1992; 44(6):655-61. PubMed ID: 1305961
[TBL] [Abstract][Full Text] [Related]
10. Combination of the bioreductive drug tirapazamine with the chemotherapeutic prodrug cyclophosphamide for P450/P450-reductase-based cancer gene therapy.
Jounaidi Y; Waxman DJ
Cancer Res; 2000 Jul; 60(14):3761-9. PubMed ID: 10919648
[TBL] [Abstract][Full Text] [Related]
11. Adaptation of human tumor cells to tirapazamine under aerobic conditions: implications of increased antioxidant enzyme activity to mechanism of aerobic cytotoxicity.
Elwell JH; Siim BG; Evans JW; Brown JM
Biochem Pharmacol; 1997 Jul; 54(2):249-57. PubMed ID: 9271329
[TBL] [Abstract][Full Text] [Related]
12. Purification and properties of cytochrome P-450 and NADPH-cytochrome c (P-450) reductase from human liver microsomes.
Kamataki T; Sugiura M; Yamazoe Y; Kato R
Biochem Pharmacol; 1979 Jul; 28(13):1993-2000. PubMed ID: 113009
[No Abstract] [Full Text] [Related]
13. Exploiting the Inherent Photophysical Properties of the Major Tirapazamine Metabolite in the Development of Profluorescent Substrates for Enzymes That Catalyze the Bioreductive Activation of Hypoxia-Selective Anticancer Prodrugs.
Shen X; Laber CH; Sarkar U; Galazzi F; Johnson KM; Mahieu NG; Hillebrand R; Fuchs-Knotts T; Barnes CL; Baker GA; Gates KS
J Org Chem; 2018 Mar; 83(6):3126-3131. PubMed ID: 29461834
[TBL] [Abstract][Full Text] [Related]
14. Hydroxyl radical production in a purified NADPH--cytochrome c (P-450) reductase system.
Lai CS; Grover TA; Piette LH
Arch Biochem Biophys; 1979 Apr; 193(2):373-8. PubMed ID: 111620
[No Abstract] [Full Text] [Related]
15. NADPH:cytochrome c (P450) reductase activates tirapazamine (SR4233) to restore hypoxic and oxic cytotoxicity in an aerobic resistant derivative of the A549 lung cancer cell line.
Saunders MP; Patterson AV; Chinje EC; Harris AL; Stratford IJ
Br J Cancer; 2000 Feb; 82(3):651-6. PubMed ID: 10682679
[TBL] [Abstract][Full Text] [Related]
16. Direct measurement of pO2 distribution and bioreductive enzymes in human malignant brain tumors.
Rampling R; Cruickshank G; Lewis AD; Fitzsimmons SA; Workman P
Int J Radiat Oncol Biol Phys; 1994 Jun; 29(3):427-31. PubMed ID: 8005794
[TBL] [Abstract][Full Text] [Related]
17. Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233).
Patterson AV; Barham HM; Chinje EC; Adams GE; Harris AL; Stratford IJ
Br J Cancer; 1995 Nov; 72(5):1144-50. PubMed ID: 7577460
[TBL] [Abstract][Full Text] [Related]
18. Enzymology of the reduction of the novel fused pyrazine mono-n-oxide bioreductive drug, RB90740 roles for P450 reductase and cytochrome b5 reductase.
Barham HM; Stratford IJ
Biochem Pharmacol; 1996 Mar; 51(6):829-37. PubMed ID: 8602879
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069.
Patterson AV; Saunders MP; Chinje EC; Talbot DC; Harris AL; Strafford IJ
Br J Cancer; 1997; 76(10):1338-47. PubMed ID: 9374381
[TBL] [Abstract][Full Text] [Related]
20. The binding of NADPH-cytochrome c reductase to rat liver microsomes.
Pokrovsky A; Mishin V; Rivkind N; Lyakhovich V
Biochem Biophys Res Commun; 1977 Aug; 77(3):912-7. PubMed ID: 409406
[No Abstract] [Full Text] [Related]
[Next] [New Search]
